Nutriband IncNASDAQ:NTRB
- LAST PRICE4.8100
- TODAY'S CHANGE (%)-0.1300 (-2.6316%)
- Bid / Lots4.5500/ 1
- Ask / Lots5.1500/ 2
- Open / Previous Close4.9936 / 4.9400
- Day Range
- 52 Week Range
- Volume12,446
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | NTRB |
|---|---|---|
| 10:09 ET | 100 | 4.9936 |
| 10:51 ET | 100 | 5.04 |
| 10:56 ET | 690 | 4.92 |
| 12:28 ET | 100 | 4.95 |
| 12:37 ET | 100 | 4.92 |
| 01:08 ET | 6131 | 4.75 |
| 01:11 ET | 2000 | 4.781 |
| 01:15 ET | 1000 | 4.89 |
| 01:24 ET | 100 | 4.7441 |
| 02:48 ET | 200 | 4.8 |
| 02:52 ET | 100 | 5.01 |
| 04:00 ET | 144 | 4.81 |
Oct 31, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Nutriband Inc | 53.4M | -5.9x | --- |
Lucid Diagnostics Inc | 53.9M | -0.9x | --- |
Modular Medical Inc | 58.1M | -2.6x | --- |
IR-Med Inc | 58.7M | -20.1x | --- |
Baird Medical Investment Holdings Ltd | 59.2M | -3.1x | --- |
Medinotec Inc | 58.7M | -2,688.2x | --- |
Company Information
Nutriband Inc. is engaged in the development of a portfolio of transdermal pharmaceutical products. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. Its development pipeline also includes AVERSA Buprenorphine and AVERSA Methylphenidate. It is developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
Contact Information
- Headquarters
- 121 S Orange Ave Ste 1500ORLANDO, FL, United States 32801-3241
- Phone
- 407-377-6695
- Fax
- ---
Executives
- Chairman of the Board, President, Secretary
- Serguei Melnik
- Chief Executive Officer, Founder, Director
- Gareth Sheridan
- Chief Financial Officer, Chief Accounting Officer
- Gerald Goodman
- Chief Operating Officer, President of 4P Therapeutics
- Alan Smith
- Chief Technical Officer
- Patrick Ryan
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $53.4M |
|---|---|
Revenue (TTM) | $1.8M |
Shares Outstanding | 11.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.39 |
EPS | $-0.81 |
Book Value | $0.73 |
P/E Ratio | -5.9x |
Price/Sales (TTM) | 29.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -402.01% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
